LncRNA Information
ID EL1102 Name PVT1 Aliases LINC00079; MYC; NCRNA00079; onco-lncRNA-100
Species Homo sapiens Chromosome 8 Start site 127794533
End site 128101253 Chain plus Exon NO. 9
Assembly Ensembl Release 89 Class lincRNA NCBI accession NR_003367
Ensembl ENSG00000249859 Sequence


Disease
Disease Method Sample Expression pattern Dysfunction type Description PMID Source
acute promyelocytic leukemia knockdown peripheral blood cells from 28 patients with de novo APL up-regulated interaction Significantly lower MYC and PVT1 expression was observed during all-trans retinoic acid (ATRA)-induced differentiation and cell cycle arrest in the APL cell line. MYC knockdown in NB4 cells led to PVT1 downregulation. Moreover, PVT1 knockdown by RNA interference led to suppression of the MYC protein level, and cell proliferation was inhibited. 26544536
non-small cell lung cancer knockdown of PVT1 inhibited NSCLC cell proliferation and induced apoptosis both in vitro and in vivo 105 human NSCLC tissues up-regulated N/A High expression of PVT1 was associated with a higher TNM stage and tumor size 26908628
gastric cancer microarray, qPCR etc. gastric cancer tissues, cell lines (SGC7901) up-regulated expression PVT1 showed higher expression in human gastric cancer tissues than in adjacent non-cancerous tissues and in SGC7901 paclitaxel-resistant cells compared with SGC7901 cells. PVT1 expression was correlated with lymph node invasion of gastric cancer. 25258543 Lnc2Cancer
malignant pleural mesothelioma microarray, qPCR, knockdown etc. MPM tissue, MPM cell lines up-regulated N/A Our results suggest that C-MYC and PVT1 CNG promotes a malignant phenotype of MPM, with C-MYC CNG stimulating cell proliferation and PVT1 both stimulating proliferation and inhibiting apoptosis. 24926545 Lnc2Cancer
colorectal cancer microarray, qPCR, Western blot, knockdown etc. CRC tissue, cell lines (RKO, HCT116 etc.) up-regulated N/A CRC cells transfected with PVT-1 siRNA exhibited significant loss of their proliferation and invasion capabilities. In these cells, the TGFβ1 signalling pathway and apoptotic signals were significantly activated. In addition, univariate and multivariate analysis revealed that PVT-1 expression level was an independent risk factor for overall survival of colorectal cancer patients. 24196785 Lnc2Cancer
prostate cancer microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) up-regulated N/A Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. 23728290 Lnc2Cancer
type 2 diabetes mellitus N/A N/A N/A mutation Identification of PVT1 (rs2720709, A>G) as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study. 17395743 LncRNADisease
Burkitt's lymphoma N/A N/A N/A mutation PVT1 is frequently involved in the translocations occurring in variant Burkitt's lymphomas and murine plasmacytomas. 17503467 LncRNADisease
murine plasmacytomas N/A N/A N/A mutation PVT1 is frequently involved in the translocations occurring in variant Burkitt's lymphomas and murine plasmacytomas. 17503467 LncRNADisease
renal cancer N/A N/A N/A mutation Variants (rs13447075, A>C;rs2648862, A>C) in the plasmacytoma variant translocation gene (PVT1) are associated with end-stage renal disease attributed to type 1 diabetes. 17881614 LncRNADisease
cleft lip N/A N/A N/A mutation Association identified by GWAS (rs987525,A>G). 19270707 LncRNADisease
Hodgkin's lymphoma N/A N/A N/A N/A PVT1 is a new susceptibility loci for this disease. 21037568 LncRNADisease
type 1 diabetes mellitus N/A N/A N/A mutation There is association between variants (rs2720709, A>G) in the plasmacytoma variant translocation 1 gene (PVT1) and end-stage renal disease (ESRD) attributed to both type 1 and type 2 diabetes. 21526116 LncRNADisease
type 2 diabetes mellitus N/A N/A N/A mutation There is association between variants (rs2720709, A>G) in the plasmacytoma variant translocation 1 gene (PVT1) and end-stage renal disease (ESRD) attributed to both type 1 and type 2 diabetes. 21526116 LncRNADisease
diabetic nephropathy N/A N/A N/A Interaction PVT1 may mediate the development and progression of diabetic nephropathy through mechanisms involving ECM accumulation. 21526116 LncRNADisease
diabetic nephropathy N/A N/A N/A regulation Role of MicroRNA 1207-5P and Its Host Gene, the Long Non-Coding RNA Pvt1, as Mediators of Extracellular Matrix Accumulation in the Kidney: Implications for Diabetic Nephropathy. 24204837 LncRNADisease
lymphoma N/A N/A N/A N/A Burkitt lymphoma association 2470097 LncRNADisease
cancer N/A N/A N/A N/A A single supernumerary segment encompassing all four genes(Myc gene or the region encompassing Pvt1, Ccdc26 and Gsdmc ) successfully promotes cancer; PVT1 RNA and MYC protein expression correlated in primary human tumours, and copy number of PVT1 was co-increased in more than 98% of MYC-copy-increase cancers. 25043044 LncRNADisease
cancer N/A N/A N/A expression The PVT gene frequently amplifies with MYC in tumor cells. 2725491 LncRNADisease
lymphoma N/A N/A N/A N/A Burkitt lymphoma association 3024964 LncRNADisease
breast cancer qPCR etc. cell lines (A2780, DOV13, PA-1 etc.) up-regulated expression Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. 17908964 LncRNADisease Lnc2Cancer
ovarian cancer qPCR etc. cell lines (A2780, DOV13, PA-1 etc.) up-regulated expression Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. 17908964 LncRNADisease Lnc2Cancer
pancreatic cancer qPCR etc. cell line (ASPC-1) up-regulated expression PVT1 gene as a regulator of Gemcitabine sensitivity and showed that functional inactivation of the PVT1 gene led to enhanced Gemcitabine sensitivity in human pancreatic cancer ASPC-1 cells. 21316338 LncRNADisease Lnc2Cancer
breast cancer qPCR etc. breast cancer tissue, cell lines (BRF71T1, HCC38, HCC1143 etc.) up-regulated N/A In the 43 breast cancer tissues, PVT1 expression was significantly higher in those with the GG genotype than that in the GA or AA genotype. Compared to normal tissues with any of the genotypes, PVT1 expression was also higher in the tumors with the GG genotype. These findings suggest that the GG genotype of SNP rs13281615 influences breast cancer development likely by modulating PVT1 expression. 24780616 Lnc2Cancer
hepatocelluar carcinoma qPCR etc. cell lines (HepG2, LM3, SMMC-7721) up-regulated N/A Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2 25043274 LncRNADisease Lnc2Cancer
hepatocelluar carcinoma qPCR etc. HCC tissue, cell lines (Huh7, SK-hep1, SMMC-7721, HepG2, Hep3B, PLC/PRF/5, Bel-7402) up-regulated expression The relative expression levels of PVT1 were significantly higher in cancerous tissues compared with the corresponding non-cancerous tissues. Furthermore, overexpression of PVT1 was associated with a higher serum a-fetoprotein expression level and a higher recurrence rate. Kaplan-Meier analysis indicated that the patients with high PVT1 expression exhibited poor recurrence-free survival, and multivariate analysis demonstrated that high levels of PVT1 expression are an independent predictor for HCC recurrence. 25624916 Lnc2Cancer
pancreatic ductal adenocarcinoma qPCR etc. PDAC tissue up-regulated expression The study results showed that the PVT1 expression was significantly increased in PDAC tissues compared to adjacent nontumor tissues. The expression of PVT1 was associated with clinical stage and N-classification (P<0.05). Patients with high PVT1 expression level had shorter overall survival times compared to those with low PVT1 expression level (P<0.05). 25668599 Lnc2Cancer
gastric cancer qPCR etc. gastric cancer tissue, cell lines(AGS, MKN45, 7901 etc.) up-regulated expression All the 8 lncRNAs were then subjected to qPCR validation using 20 pairs of GC and control tissues. Among them, HOTAIR, PVT1, H19, MALAT1, GHET1 and HULC were significantly higher in tumor tissues compared with control tissues. 26096073 Lnc2Cancer
prostate cancer qPCR, ChIP etc. cell lines (PC3, 1542-CP) differential expression mutation The risk allele (G) of rs378854 (A>G) reduces binding of the transcription factor YY1 in vitro. The region surrounding rs378854 interacts with the MYC and PVT1 promoters.Expression of the PVT1 oncogene in normal prostate tissue increased with the presence of the risk allele of rs378854, while expression of MYC was not affected. 21814516 LncRNADisease Lnc2Cancer
multiple myeloma qPCR, FISH etc. cell lines (AMU-MM1, KMS-12-BM, KMS-18, KMS-20 etc.) differential expression N/A PVT1 rearrangements were most common and found in 7 of 12 patients (58.3%) and 5 of 8 cell lines (62.5%) with 8q24 abnormalities. A combination of spectral karyotyping (SKY), FISH, and oligonucleotide array identified several partner loci of PVT1 rearrangements, such as 4p16, 4q13, 13q13, 14q32, and 16q23-24. The PVT1-NBEA chimera in which PVT1 exon 1 was fused to NBEA exon 2 and the PVT1-WWOX in which PVT1 exon 1 was fused to WWOX exon 9 were associated with the expression of abnormal NBEA and WWOX lacking their N-terminus, respectively. These findings suggest that PVT1 rearrangements may represent a novel molecular paradigm underlying the pathology of 8q24 rearrangement-positive multiple myeloma. 22869583 Lnc2Cancer
non-small cell lung cancer qPCR, knockdown etc. NSCLC tissue, cell lines (A549, H157, HEK-293T) up-regulated expression lncRNA PVT1 expression was significantly upregulated in NSCLC tissues and lung cancer cells. Increased PVT1 expression was significantly correlated with histological grade and lymph node metastasis. In addition, NSCLC patients with PVT1 higher expression have shown significantly poorer overall survival than those with lower PVT1 expression. In vitro assays our results indicated that knockdown of PVT1 inhibited cell proliferation, migration, and invasion. 25400777 Lnc2Cancer
bladder cancer qPCR, knockdown, Flow cytometry assay etc. bladder cancer tissue, cell lines (T24, 5637) up-regulated expression Here, we found that PVT1 was upregulated in bladder cancer tissues and cells. Further experiments revealed that PVT1 promoted cell proliferation and suppressed cell apoptosis. 26517688 Lnc2Cancer
gastric cancer qPCR, Western blot etc. gastric cancer tissue, cell lines (BGC823, SGC7901 etc.) up-regulated N/A Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance 25956062 LncRNADisease Lnc2Cancer
non-small cell lung cancer qPCR, Western blot, knockdown etc. NSCLC lines (A549, H157, H226, H460, HCC827) up-regulated expression Our results indicated that PVT1 expression was significantly increased in NSCLC tissues and cell lines, and its upregulation was associated with advanced T-stage and tumor-node-metastasis (TNM) stage and regional lymph node metastasis. PVT1 expression levels were robust in differentiating NSCLC tissues from controls 26493997 Lnc2Cancer
thyroid cancer qPCR, Western blot, RIP, ChIP etc. thyroid cancer tissues, cell lines (IHH-4, FTC-133, 8505C) up-regulated interaction Compared to the controls, lncRNA PVT1 was significantly up-regulated in thyroid tissues, as well as in three kinds of tumor cell lines (P < 0.05). Silenced PVT1 significantly inhibited thyroid cell line IHH-4, FTC-133, and 8505C cell proliferation and arrested cell cycle at G0/G1 stage and significantly decreased cyclin D1 and TSHR expressions (P < 0.05). Moreover, lncRNA PVT1 could be enriched by EZH2, and silencing PVT1 resulted in the decreased recruitment of EZH2 26427660 Lnc2Cancer
ovarian cancer qRT-PCR ovarian cancer tissues of cisplatin-resistant patients and cisplatin-sensitive patients up-regulated N/A Overexpression of LncRNA PVT1 in ovarian cancer promotes cisplatin resistance by regulating apoptotic pathways 26884974
gastric cancer QRT-PCR assay 111pairs of gastric cancer and adjacent normal tissues up-regulated N/A up-regulation was significantly correlated to invasion depth and regional lymph nodes metastasis 26925791
gastric cancer qRT-PCR, MTT and colony formation assays, RIP GC tissues and cell lines up-regulated expression The higher expression of PVT1 was significantly correlated with deeper invasion depth and advanced TNM stage. Further experiments demonstrated that PVT1 knockdown significantly inhibited the proliferation both in vitro and in vivo. These results suggest that lncRNA PVT1 may serve as a candidate prognostic biomarker and target for new therapies in human gastric cancer. 25890171
 


Interaction
Interaction target Level of interaction Type of interaction Description PMID Source
c-Myc DNA-TF regulation PVT-1 regulates c-Myc gene transcription over a long distance. PVT-1 is also a downstream target of Myc proteins. 17503467 LncRNADisease
c-Myc RNA-DNA regulation PVT-1 regulates c-Myc gene transcription over a long distance. PVT-1 is also a downstream target of Myc proteins. 17503467 LncRNADisease
YY1 RNA-DNA regulation The risk allele (G) of rs378854 reduces binding of the transcription factor YY1 in vitro. The region surrounding rs378854 interacts with the MYC and PVT1 promoters.Expression of the PVT1 oncogene in normal prostate tissue increased with the presence of the risk allele of rs378854, while expression of MYC was not affected. 21814516 LncRNADisease
P53 DNA-TF regulation The non-protein coding locus PVT1 is a p53-inducible target gene. 22110125 LncRNADisease
serum α-fetoprotein RNA-Protein regulation overexpression of PVT1 was associated with a higher serum α-fetoprotein expression level (P=0.011) and a higher recurrence rate (P=0.004). 25624916
EZH2 RNA-Protein binding we further confirmed that PVT1 was associated with enhancer of zeste homolog 2 (EZH2) and that this association was required for the repression of p15 and p16 25890171
EZH2 RNA-Protein regulation lncRNA PVT1 could be enriched by EZH2, and silencing PVT1 resulted in the decreased recruitment of EZH2. 26427660
cyclin D1 and TSHR RNA-Protein regulation Silenced PVT1significantly decreased cyclin D1 and TSHR expressions. 26427660
MYC DNA-DNA regulation Significantly lower MYC and PVT1 expression was observed during all-trans retinoic acid (ATRA)-induced differentiation and cell cycle arrest in the APL cell line. MYC knockdown in NB4 cells led to PVT1 downregulation. Moreover, PVT1 knockdown by RNA interference led to suppression of the MYC protein level, and cell proliferation was inhibited. 26544536
LATS2 RNA-DNA regulation PVT1 recruits EZH2 to the large tumor suppressor kinase 2 (LATS2) promoter and represses LATS2 transcription. 26908628
EZH2 RNA-Protein binding PVT1 recruits EZH2 to the large tumor suppressor kinase 2 (LATS2) promoter and represses LATS2 transcription. 26908628